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INTRODUCTION
Cartilage is developed by the differentiation of mesenchy-
mal cells into chondrocytes (1). Differentiated chondrocytes
in articular cartilage maintain homeostasis by synthesizing
cartilage-specific matrix molecules. However, this home-
ostasis is destroyed during pathogenesis of cartilage disease,
such as arthritis. Cartilage destruction during arthritis in-
volves the loss of differentiated phenotype (dedifferentiation)
and apoptotic death of chondrocytes, which is caused by the
production of pro-inflammatory cytokines such as interleukin
(IL)-1 (2).
Peroxisome proliferator-activated receptor (PPAR)- is a
member of the nuclear receptor superfamily of ligand-depen-
dent transcription factors. PPAR- forms a heterodimeric
complex with the retinoid X receptor (3) and binds to spe-
cific nucleotide motifs (direct repeats with single spacing,
DR1) located in the promoter of target genes. It was origi-
nally characterized as a regulator of adipocyte differentiation
and lipid metabolism (4, 5). Recently, PPAR- was also shown
to be expressed in other cell types, including endothelial cells
and chondrocytes (6, 7). PPAR- ligands inhibit the IL-1 -
induced nitric oxide (NO) and matrix metalloproternase-13
(MMP-13) production, as well as a decrease of proteoglycan
synthesis (8). The presence of the expression of the PPAR-
in chondrocytes may provide a new insight in the understand-
ing of the mechanisms which lead to the loss of cartilage
homeostasis.
The cyclopentenone prostaglandins (PGs) are important
regulators of cellular function in a variety of tissues, includ-
ing bone and cartilage. PGD2 is a mediator of allergy and
inflammation (9). PGJ2 is formed within the cyclopentenone
ring of the endogenous prostaglandin PGD2 by a nonenzy-
matic reaction. PGJ2 is metabolized further to yield  12-PGJ2
and 15-deoxy- 12,14 PGJ2 (15d-PGJ2). The PGJ family is
involved in mediating various biological effects including the
regulation of cell cycle progression and inflammatory respons-
es (10). In contrast to classical PGs, which bind to cell sur-
face G protein-coupled receptors, 15d-PGJ2 is a natural li-
gand of a nuclear receptor, PPAR- . This receptor behaves
as a ligand-activated transcription factor through its DNA
binding domain, which recognizes response elements in the
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ERK-1/-2 and p38 Kinase Oppositely Regulate 15-deoxy-△
12,14-
prostaglandinJ2-Induced PPAR- Activation That Mediates Dedifferen-
tiation But Not Cyclooxygenase-2 Expression in Articular Chondrocytes
Peroxisome proliferator-activated receptor gamma (PPAR- ) is a ligand-activated
transcription factor and plays an important role in growth, differentiation, and inflam-
mation in different tissues. In this study, we investigated the effects of 15d-PGJ2, a
high-affinity ligand of PPAR- , on dedifferentiation and on inflammatory responses
such as COX-2 expression and PGE2 production in rabbit articular chondrocytes
with a focus on ERK-1/-2, p38 kinase, and PPAR- activation. We report here that
15d-PGJ2 induced dedifferentiation and/or COX-2 expression and subsequent PGE2
production. 15d-PGJ2 treatment stimulated activation of ERK-1/-2, p38 kinase, and
PPAR- . Inhibition of ERK-1/-2 with PD98059 recovered 15d-PGJ2-induced dedif-
ferentiation and enhanced PPAR- activation, whereas inhibition of p38 kinase
with SB203580 potentiated dedifferentiation and partially blocked PPAR- activa-
tion. Inhibition of ERK-1/-2 and p38 kinase abolished 15d-PGJ2-induced COX-2
expression and subsequent PGE2 production. Our findings collectively suggest that
ERK-1/-2 and p38 kinase oppositely regulate 15d-PGJ2-induced dedifferentiation
through a PPAR- -dependent mechanism, whereas COX-2 expression and PGE2
production is regulated by ERK-1/-2 through a PPAR- -independent mechanism
but not p38 kinase in articular chondrocytes. Additionally, these data suggest that
targeted modulation of the PPAR- and mitogen-activated protein kinase pathway
may offer a novel approach for therapeutic inhibition of joint tissue degradation.
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promoter of some target genes linked to apoptosis, cell pro-
liferation, and differentiation and inflammation (11, 12).
Recent data showed the presence of PPAR- in rat cartilage
and human synovial tissues (5) and indicated that 15d-PGJ2
is the most potent endogenous ligand for PPAR- yet dis-
covered (13). 
Mitogen-activated protein (MAP) kinases are serine/thre-
onine kinases that regulate a variety of processes, including
cell growth, proliferation, apoptosis, and extracellular matrix
accumulation. Our previous studies in articular chondrocytes
indicated that NO caused apoptosis and dedifferentiation,
which are mediated by MAP kinases subtypes extracellular
signal-regulated protein kinase (ERK) and p38 kinase (14).
These MAP kinases play opposing roles, with activated ERK-
1/-2 inducing dedifferentiation, COX-2 expression, and in-
hibiting NO-induced apoptosis, while p38 kinase signaling
triggers apoptosis, COX-2 expression, and maintains the
differentiated status. 
Other recent studies have identified PPAR- as a substrate
of mitogen-activated protein kinases (15). The transcription-
al activity of PPAR- is positively modulated by ligand bind-
ing and negatively regulated by phosphorylation mediated
by the MEK/ERK signaling pathway. Also, PPAR- is effi-
ciently phosphorylated by JNK/SAPK (c-Jun N-terminal
kinase or stress-activated protein kinase) but only weakly
phosphorylated by p38 (4). Evidence that 15d-PGJ2 modu-
lates MAP kinase activity is conflicting. It has been shown
that 15d-PGJ2 activates JNK in untreated HeLa cells (16),
but blocks IL-1-induced JNK phosphorylation in rodent
pancreatic islets (17). Similarly, induction of macrophage
apoptosis by 15d-PGJ2 was shown to depend on the p38
MAP kinase; however, 15d-PGJ2 appeared to decrease phos-
phorylation of p38 (18), a step necessary for its activity. These
data imply that the effects of 15d-PGJ2 on MAP kinases may
be cell-context specific.
Therefore, in this study, we investigated whether PPAR-
activators may modulate the differentiation and inflammatory
responses (COX-2 expression/PGE2 production) in primary
culture rabbit articular chondrocytes. We additionally char-
acterized the signaling mechanism of regulation of 15d-PGJ2-
induced dedifferentiation and inflammation, focusing on the
roles of MAP kinases. Here, we report that 15d-PGJ2-induced
dedifferentiation and COX-2 expression/PGE2 production
is regulated by modulation of MAP kinases activation.
MATERIALS AND METHODS
Isolation and monolayer culture of rabbit articular 
chondrocytes 
Rabbit articular chondrocytes were isolated from the car-
tilage of 2-week-old New Zealand white rabbits as described
previously (19). Cartilage slices were dissociated enzymati-
cally for 4 hr in 0.2% collagenase type II (381 U/mg solid,
Sigma) in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco-BRL, Gaithersburg, MD, U.S.A.). Individual cells
were suspended in DMEM supplemented with 10% (v/v)
fetal bovine-calf serum, 50  g/mL streptomycin, and 50
units/mL penicillin and plated on culture dishes at a density
of 5×104 cells/cm2. After 4 days in culture, the cells were
treated with the indicated pharmacological reagents for 1 hr
prior to 15d-PGJ2 (Calbiochem, San- diego, CA, U.S.A.),
such as SB203580 (Calbiochem) to inhibit p38 kinase and
PD98059 (Calbiochem) to inhibit MEK-1/-2. The trans-
fected cells, which were cultured in complete medium for
24 hr, were used for further analysis as indicated in each exper-
iment. Differentiation status of articular chondrocytes was
determined by immunoblot analysis by examining the expres-
sion of type II collagen as described below. Alternatively, cells
cultured for various time periods were stained with Alcian
blue to localize the sulfated cartilage matrix. Alcian blue
bound to sulfated glycosaminoglycans was extracted with 4
M guanidine-HCl and quantitated by measuring the absor-
bance at 600 nm.
Immunoblot analysis
Whole cell lysates were prepared by extracting proteins
using a buffer containing 50 mM Tris-HCl, pH 7.4, 150
mM NaCl, 1% Nonidet P-40, and 0.1% sodium dodecyl-
sulfate (SDS), supplemented with protease inhibitors (10 g/
mL leupeptin, 10  g/mL pepstatin A, 10  g/mL aprotinin
and 1 mM of 4-[2-aminoethyl]benzenesulfonyl fluoride)and
phosphatase inhibitors (1 mM NaF and 1 mM Na3VO4). The
proteins were size-fractionated by SDS-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane.
The nitrocellulose sheet was then blocked with 3% non-fat
dry milk in Tris-buffered saline. The following antibodies
were used: anti-COX-2 (Cayman Chemical Ann Arbor, MI,
U.S.A.), pp38 (Cell signaling, Beverly, MA, U.S.A.), pERK,
ERK-2, p38, PPAR- , and SOX-9 (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, U.S.A.), and type II collagen (Che-
micon, Temecula, CA, U.S.A.). Blots were developed using
a peroxidase-conjugated secondary antibody on a chemilu-
minescence system.
PGE2 assay
PGE2 production was determined by measuring the levels
of cellular and secreted PGE2 using an assay kit (Amersham
Pharmacia Biotech, NJ, U.S.A.). Briefly, chondrocytes were
seeded in standard 96-well microtiter plates at 2×104 cells/
well. Following addition of the indicated pharmacological
reagents, the supernatant was used to quantify the amount of
PGE2, according to the manufacturer’s protocol. PGE2 levels
were calculated using a PGE2 standard curve.Cartilage explant culture and immunohistochemistry 
Rabbit joint cartilage explants (~125  L) were fixed in 4%
paraformaldehyde in PBS for 24 hr at 4℃, washed with PBS,
dehydrated in ethanol, embedded in paraffin, and section-
ed at 4  m thickness as described previously (23). The sec-
tions were stained by standard procedures using antibodies
against type II collagen and COX-2 and Alcian blue stain-
ing, and visualized by developing with a kit purchased from
DAKO (Carpinteria, CA, U.S.A.), following the procedure
recommended by the manufacturer. 
Immunofluorescence microscopy
Expression and distribution of type II collagen and COX-
2 in rabbit articular chondrocytes were determined by indi-
rect immunofluorescence microscopy, as described previous-
ly (19). Briefly, chondrocytes were fixed with 3.5% parafor-
maldehyde in PBS for 10 min at room temperature. The cells
were permeabilized and blocked with 0.1% Triton X-100
and 5% fetal calf serum in PBS for 30 min. The fixed cells
were washed and incubated for 1 hr with antibody (10  g/
mL) against type II collagen and COX-2. The cells were
washed, incubated with rhodamine- or fluorescein-conju-
gated secondary antibodies for 30 min, and observed under
a fluorescence microscope. 
Transfection and reporter assays
The reporter construct (3xPPRE-TK-luc/pGL3) used in
the transfections contained three copies of the PPRE site
from the aP2 enhancer (ARE7) inserted upstream of a mini-
mal thymidine kinase (TK) promoter in the pGL3 basic lu-
ciferase vector and RXR cDNA (a gift from Dr. JB, Kim
at Seoul National University). Transfection of the reporter
vector was performed as described previously (20). Chondro-
cytes were grown in 10% fetal calf serum/DMEM and co-
transfected with various reporter plasmids (1  g) and pCMV
-galactosidase plasmid (Clontech) using Lipofectamine (Life
Technologies, Inc., Grand island, NY, U.S.A.), following the
procedure recommended by the manufacturer. The trans-
fected cells were cultured in complete medium for 24 hr and
used for further assay. Cells were treated with increasing con-
centrations (0-20  M) or times (0-24 hr) of 15d-PGJ2. Cell
extracts were assayed for luciferase activity. Luciferase and  -
galactosidase activities were determined using a luciferase
assay (Promega, Madison, WI, U.S.A.) and Galacto-light
system (Tropix, Inc., Bedford, MA, U.S.A.). The activities
were corrected for transfection efficiency with  -gal activity
and expressed as fold-induction relative to the level in untreat-
ed cells. Each assay was performed in triplicate. 
Data analyses and statistics
The results are expressed as the means±S.D. (Standard
Deviation) values calculated from the specified number of
determinations. Student’s t-test was used to compare indivi-
dual treatments with their respective control values. A proba-
bility of p<0.05 was taken as denoting a significant difference.
RESULTS
15d-PGJ2 causes dedifferentiation in articular chondrocytes
Rabbit articular chondrocytes in primary culture were treat-
ed with the natural ligand of PPAR- , 15d-PGJ2. 15d-PGJ2-
treated chondrocytes suppress type II collagen (a marker for
differentiation of chondrocytes) and SOX-9 (a major transcrip-
tion factor that regulates type II collagen expression) expres-
sion in a time- and dose-dependent manner as determined
by immunoblot analysis (Fig. 1A). As expected, 15d-PGJ2
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Fig. 1. 15d-PGJ2 treatment of primary culture cells induces dedifferentiation. (A) Rabbit joint articular chondrocytes were treated with 10
M 15d-PGJ2, the PPAR- activator, for the indicated time periods (upper panel, A) or with the indicated concentrations of 15d-PGJ2 for
24 hr (lower panel, A). Expression of type II collagen and SOX-9 was detected using immunoblot analysis. (B) Cartilage explants were
untreated or treated with 10  M 15d-PGJ2 for 24 hr. Type II collagen and proteoglycan were detected by immunohistochemical staining
(×400) and Alcian blue staining (×400), respectively. (C , D) Chondrocytes were treated for the indicated time periods with 10  M 15d-
PGJ2 (C) of with the indicated concentrations of 15d-PGJ2 for 24 hr (D). Accumulation of sulfated glycosaminoglycan was quantified by
Alcian blue staining. The data represent results of a typical experiment (A, B) or mean values±S.D. (C, D) from at least four independent
experiments. *, p<0.05; 
� , p<0.01 compared with untreated cells.
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treatment of cartilage explants blocked type II collagen ex-
pression and accumulation of sulfated proteoglycan, as deter-
mined via immunohistochemistry and Alcian blue staining,
respectively (Fig. 1B). Consistent with the expression pat-
tern of type II collagen, 15d-PGJ2 treatment led to a time-
and dose-dependent decrease in the accumulation of sulfat-
ed proteoglycan (Fig. 1C, D). These results indicate that 15d-
PGJ2 induces dedifferentiation of articular chondrocytes in
both primary culture cells and cartilage explants.
15d-PGJ2-induced COX-2 expression and PGE2
production of chondrocytes
The effect of 15d-PGJ2 on COX-2 expression and PGE2
production was investigated using both primary culture chon-
drocytes and cartilage explant cultures. In primary culture
chondrocytes, 15d-PGJ2 increased protein levels of COX-2 in
a time- and dose-dependent manner as determined by immu-
noblot analysis (Fig. 2A). COX-2 was increased 1 hr after
15d-PGJ2 treatment, and levels peaked at 12 hr. In cartilage
explants, 15d-PGJ2 stimulated COX-2 expression as deter-
mined by immunohistochemical staining (Fig. 2B). Consis-
tent with the induction of COX-2 expression, 15d-PGJ2 stim-
ulated PGE2production (Fig. 2C) that was detectable 3 hr after
15d-PGJ2 addition (Fig. 2D). These data indicate that 15d-
PGJ2 not only causes dedifferentiatin of articular chondrocytes
but also stimulates COX-2 expression and PGE2 production.
15d-PGJ2 stimulated ERK-1/-2, p38 kinase and PPAR-
activation in chondrocytes
To investigate the signaling pathway stimulating dediffer-
entiation and/or COX-2 expression and PGE2 production of
15d-PGJ2-treated chondrocytes, we initially examined changes
in the activity of ERK-1/-2 and p38 kinase. These two sub-
types were selected for study, based on results from previous
data (25) indicating that the proteins conversely regulate
chondrocyte differentiation. When cells were treated with
15d-PGJ2, the ERK-1/-2 activity was transiently increased,
as determined by immunoblot analysis with anti-phospho-
ERK-1/-2 antibody (Fig. 3). Levels of ERK-1/-2 phospho-
rylation began to increase at 15 min, sustained levels at 1 hr,
and decreased thereafter. Similar to the pattern of ERK acti-
vation, the p38 kinase activity was also transiently increased
in 15d-PGJ2-treated cells (Fig. 3). The effects of 15d-PGJ2
on ERK-1/-2 and p38 kinase activity were time-dependent. 
In an attempt to elucidate the role of PPAR- in 15d-PGJ2-
induced dedifferentiation and COX-2 expression, we first
determined the expression and transcription activity. As shown
in Fig. 4A, 15d-PGJ2 treatment did not affect PPAR- ex-
pression, but caused activation of PPAR- in a time- and
dose-dependent manner (Fig. 4B, C). These results show
that 15d-PGJ2 caused activation of ERK-1/-2, p38 kinase
and PPAR- in articular chondrocytes.
Opposite roles of ERK-1/-2 and p38 kinase in 15d-PGJ2-
induced dedifferentiation through a PPAR- -dependent
pathway of chondrocytes
The role of ERK-1/-2 and p38 kinase in 15d-PGJ2-in-
Fig. 2. 15d-PGJ2 treatment of primary culture cells increases COX-2 expression and PGE2 production. (A) Primary culture chondrocytes
were treated with 15d-PGJ2 (10  M) for various time periods (upper panel) or with the indicated concentrations of 15d-PGJ2 for 24 hr (lower
panel). COX-2 expression was determined by immunoblot analysis. (B) Articular chondrocytes were untreated or treated with 10  M 15d-
PGJ2 for 24 hr, and COX-2 expression was determined by immunohistochemical staining (×400). (C, D) Chondrocytes were treated for
the indicated time periods with 10  M 15d-PGJ2 (C) or with the indicated concentrations of 15d-PGJ2 for 24 hr (D). Levels of cellular and
secreted PGE2 were determined by a assay kit. The data in A and B represent results of a typical experiment, and the data in C-D repre-
sent mean values±S.D. (n=4). *, p<0.05; 
� , p<0.01 compared with untreated cells.
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Fig. 3. 15d-PGJ2 treatment of primary culture cells stimulates ERK-
1/-2 and p38 kinase activation. Chondrocytes were treated with
10 M  15d-PGJ2 for the indicated periods. ERK-1/-2 and p38 ki-
nase phosphorylation were detected using immunoblot analysis
with anti-phospho-ERK-1/-2 and anti-phospho-p38 kinase anti-
bodies. The data represent results of a typical experiment. 
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15d-PGJ2 (10 M)duced dedifferentiation and COX-2 expression of chondro-
cytes was next investigated. The addition of SB203580 to
15d-PGJ2-treated chondrocytes accelerated the decreased
type II collagen expression (Fig. 5A, upper panel) and pro-
teoglycan synthesis (Fig. 5B) in a dose-dependent manner.
SB203580 completely blocked both 15d-PGJ2-stimulated
COX-2 expression (Fig. 5A, upper panel) and PGE2 produc-
tion (Fig. 5C) and partially suppressed PPAR- activation
(Fig. 5D). In contrast to the effects of p38 kinase inhibition,
the blockade of ERK-1/-2 blocked 15d-PGJ2-induced decrease
of type II collagen expression (Fig. 5A, lower panel) and pro-
teoglycan synthesis (Fig. 5B). PD98059 partially blocked
15d-PGJ2-stimulated COX-2 expression (Fig. 5A, lower
panel) but completely blocked PGE2 production (Fig. 5C),
and potentiated PPAR- activation (Fig. 5D). Addition of
PD98059 or SB203580 to 15d-PGJ2-treated chondrocytes
displayed no cytotoxicity, as assessed by the conversion of a
tetrazolium compound to its formazan product, as well as
trypan blue exclusion (data not shown). Taken together, these
results indicate that 15d-PGJ2-induced dedifferentiation is
regulated by ERK-1/-2 activity but not by p38 kinase activ-
ity via PPAR- -dependent mechanism, whereas 15d-PGJ2-
induced COX-2 expression and PGE2 production is regulat-
ed by ERK-1/-2 and p38 kinase via PPAR- -independent
and -dependent mechanism, respectively. 
DISCUSSION
Articular cartilage is a major component of the joint, and
its mechanical properties depend on the integrity of the ex-
tracellular matrix, which is composed mainly of proteogly-
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Fig. 4. 15d-PGJ2 treatment of primary culture cells stimulates PPAR- transcriptional activity. (A) Chondrocytes were treated with 10  M
15d-PGJ2 for the indicated periods (upper panel), or with the indicated concentrations of 15d-PGJ2 for 24 hr (lower panel). (B, C) Primary
culture chondrocytes cells were co-transfected with reporter plasmids (3xPPRE-TK-Luc/pGL3) and RXR expression plasmids (RXR /
pSG5). pCMV  -galactosidase plasmid was used as an internal control for the transfection efficiency. Transfected cells were treated with
15d-PGJ2 (10  M) for various time periods (B) or with the indicated concentrations of 15d-PGJ2 for 24 hr (C). The cell extracts were assayed
for luciferase activity and  -galactosidase activity. The data in A represent results of a typical experiment, and the data in B-C represent
mean values±S.D. (n=4). *, p<0.05; 
� , p<0.01 compared with untreated cells.
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01 51 0 2 0 ( M)cans and collagens (21). Chondrocytes in normal articular
cartilage are a unique cell type in that their differentiated
phenotype is reversible. Chondrocyte phenotype is regulat-
ed by a balance of anabolic and catabolic molecular reactions
that are involved in maintaining homeostasis of cartilage
tissue (2). Differentiated chondrocytes lose their phenotype
and transform into fibroblasts-like cells upon exposure to
soluble factors such as IL-1 (22), retinoic acid (23), and NO
(24), or during serial subculture in vitro (25). Such a destruc-
tion of homeostasis is believed to be involved in the patho-
physiology of arthritis, rheumatoid arthritis (RA), and oste-
oarthritis (OA) (2, 26). Several inflammatory mediators, in-
cluding NO and PG, have been implicated in the disease
process of RA and OA. PGs are produced by cytokine-stim-
ulated chondrocytes in arthritis-affected cartilage via induc-
tion of COX-2 expression (27).
In this study, we demonstrated that 15d-PGJ2 caused a
loss of differentiated chondrocyte phenotype as demonstrat-
ed by inhibition of type II collagen expression and sulfated
proteoglycan synthesis in a time- and dose-dependent manner.
15d-PGJ2 also induced COX-2 expression and PGE2 produc-
tion. Inhibition of ERK-1/-2 with PD98059 recovered 15d-
PGJ2-induced type II collagen expression, and potentiated
PPAR- activation, whereas inhibition of p38 kinase with
SB203580 decreased the type II collagen expression, and
partially blocked PPAR- activation (Fig. 4). 15d-PGJ2-in-
duced COX-2 expression and PGE2 production is regulated
by ERK-1/-2 and p38 kinase signaling. The regulation of
COX-2 expression has been shown to occur at both transcrip-
tional and post-transcriptional levels, and structural infor-
mation on the COX-2 gene promoter revealed binding sites
for several transcription factors found in many cell types such
as NF- B and CAAT enhancer-binding protein, which are
involved in transcription factors found in many cell types
such as NF- B and CAAT enhancer-binding protein, which
are involved in transcription regulation of COX-2 (28). The
stability of COX-2 mRNA regulated by sequences within
the 3’-untranslated region is also an important regulatory
mechanism of COX-2 expression (29). In addition, several
studies linked COX-2 expression with MAPK subtypes in-
cluding ERK-1/-2, p38 kinase, and c-Jun N-terminal kinase
(30, 31). Therefore, our observation that 15d-PGJ2-induced
expression and activity of COX-2 are regulated by ERK-1/-2
and p38 kinase signaling is consistent with the observations
of others (30, 31). We observed in this study that 15d-PGJ2-
induced dedifferentiation and/or COX-2 expression and PGE2
production are mediated by ERK-1/-2 and p38 kinase acti-
vation via PPAR- -dependent and -independent mechanism,
respectively, in rabbit articular chondrocytes.
Taken together, these results suggest that PPAR- antag-
onists may provide a new therapeutic approach for RA and
OA.
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